Conjugated To Nonproteinaceous Bioaffecting Compound (e.g., Conjugated To Cancer-treating Drug, Etc.) Patents (Class 424/181.1)
-
Publication number: 20140234345Abstract: The present application is directed to covalent conjugates between an isocarbostyril alkaloid and a lipophilic biomolecule, to pharmaceutical compositions comprising the conjugates and to therapeutic uses thereof, in particular for treating cancer.Type: ApplicationFiled: July 11, 2012Publication date: August 21, 2014Applicant: BIOLYSE PHARMA CORPORATIONInventors: Claude Mercure, Rajashree Sathyamurthy
-
Publication number: 20140227298Abstract: Tubulysin compounds of the formula (I) where R1, R2R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Inventors: Qiang CONG, Heng CHENG, Sanjeev GANGWAR
-
Publication number: 20140227296Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: March 14, 2013Publication date: August 14, 2014Inventors: Steven A. Porcelli, Maurice Zauderer
-
Publication number: 20140227297Abstract: Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Sascha N. Goonewardena, Bertram Pitt, Hong Zong
-
Publication number: 20140227299Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: GENENTECH, INC.Inventors: Robert L. Cohen, Edward HyungSuk Ha, Mark E. Reynolds
-
Publication number: 20140227180Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8802091Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.Type: GrantFiled: May 4, 2012Date of Patent: August 12, 2014Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
-
Publication number: 20140220046Abstract: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.Type: ApplicationFiled: January 15, 2014Publication date: August 7, 2014Applicant: LIPOXEN TECHNOLOGIES LIMITEDInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
-
Publication number: 20140220047Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: ApplicationFiled: February 28, 2014Publication date: August 7, 2014Applicant: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
-
Publication number: 20140219914Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: ApplicationFiled: March 11, 2014Publication date: August 7, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20140212411Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.Type: ApplicationFiled: September 19, 2013Publication date: July 31, 2014Applicants: GENENTECH, INC., IMMUNOGEN, INC.Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
-
Patent number: 8790649Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: October 28, 2011Date of Patent: July 29, 2014Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
-
Publication number: 20140205544Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: ApplicationFiled: March 5, 2014Publication date: July 24, 2014Applicant: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Patent number: 8785396Abstract: A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is designed for inhalation for delivery of drugs to the pulmonary circulation in a rapid and therapeutically effective manner.Type: GrantFiled: November 9, 2011Date of Patent: July 22, 2014Assignee: Mannkind CorporationInventors: Andrea Leone-Bay, Grayson W. Stowell, Joseph J. Guarneri, Dawn M. Carlson, Marshall Grant, Chad C. Smutney
-
Patent number: 8784817Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: February 14, 2013Date of Patent: July 22, 2014Assignee: XBiotech, Inc.Inventor: John Simard
-
Publication number: 20140199297Abstract: In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving modification with polyethylene glycol and (b) a formulation approach involving non-covalent encapsulation in antibody targeted pol(DL-lactic acid) nanoparticles.Type: ApplicationFiled: January 17, 2014Publication date: July 17, 2014Applicant: Research Foundation of the City University of New YorkInventors: Linda Saxe Einbond, Krishnaswami Raja
-
Publication number: 20140193438Abstract: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: Bristol-Myers Squibb CompanyInventors: Naidu S. Chowdari, Sanjeev Gangwar, Bilal Sufi
-
Publication number: 20140193489Abstract: The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may further comprise at least one payload; nanocapsules obtained by this method; and compositions thereof. Such compositions may be formulated for different purposes, e.g., as pharmaceutical compositions for various therapeutic or diagnostic purposes.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: BAR-ILAN UNIVERSITYInventors: Shai Rahimipour, Gil Yeroslavsky, Michal Richman
-
Publication number: 20140193437Abstract: The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicants: BioAlliance C.V., AbGenomics International Inc.Inventors: Rong-Hwa LIN, Shih-Yao LIN, Yu-Chi HSIEH, Chiu-Chen HUANG
-
Publication number: 20140178415Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Inventors: Shengfeng Li, Xiaobin Deng, Songnuan Tan, Weijia Tang, Chao Qin
-
Publication number: 20140178416Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: November 14, 2013Publication date: June 26, 2014Applicant: IMMUNOGEN, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
-
Publication number: 20140178413Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventor: Bio-Thera Solutions, Ltd. Co.
-
Publication number: 20140178412Abstract: Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Inventors: Chao Qin, Shengfeng Li
-
Publication number: 20140178414Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventor: BIO-THERA SOLUTIONS, LTD., CO.
-
Publication number: 20140178411Abstract: Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.Type: ApplicationFiled: March 15, 2013Publication date: June 26, 2014Applicant: BIO-THERA SOLUTIONS, LTD., CO.Inventors: Chao Qin, Shengfeng Li
-
Publication number: 20140170063Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: ApplicationFiled: July 23, 2013Publication date: June 19, 2014Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 8753641Abstract: The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them.Type: GrantFiled: July 20, 2009Date of Patent: June 17, 2014Assignee: University of ZurichInventors: Roger Ariel Alberto, Pascal Jean-Marie Hafliger
-
Publication number: 20140161829Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent).Type: ApplicationFiled: February 15, 2014Publication date: June 12, 2014Applicant: LegoChem Biosciences, Inc.Inventors: Yongzu Kim, Taekyo Park, Sungho Woo, Hyangsook Lee, Sunyoung Kim, Jongun Cho, Doohwan Jung, Youngun Kim, Hyunjin Kwon, Kyuman Oh, Yunseo Chung, Yun-Hee Park
-
Publication number: 20140161828Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: ApplicationFiled: December 5, 2013Publication date: June 12, 2014Applicant: AMGEN INC.Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
-
Publication number: 20140161877Abstract: Compounds that include a pederin, psymberin or pederin/psymberin chimera scaffold. The pederin scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The psymberin scaffold includes a substituent at the C8 and/or C11 positions that may include a linker that may be conjugated to a targeting moiety. The pederin/psymberin chimera scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The pederin, psymberin or pederin/psymberin chimera scaffold may be modified to include substituents at positions other than the C10 or C13 of pederin, or the C8 and C11 of psymberin.Type: ApplicationFiled: July 19, 2012Publication date: June 12, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Paul Edward Floreancig, Billy W. Day, Shuangyi Wan, Fanghui Wu
-
Patent number: 8747851Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: November 19, 2012Date of Patent: June 10, 2014Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20140154273Abstract: The invention relates to therapeutic conjugates with the ability to target various antigens. The conjugates contain a targeting antibody or antigen binding fragment thereof and an anthracycline chemotherapeutic drug. The targeting antibody and the chemotherapeutic drug are linked via a linker comprising a hydrazide moiety.Type: ApplicationFiled: September 26, 2013Publication date: June 5, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Gary L. Griffiths, Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20140141025Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.Type: ApplicationFiled: March 11, 2013Publication date: May 22, 2014Applicant: REDWOOD BIOSCIENCE, INC.Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
-
COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
Publication number: 20140140993Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Genentech, Inc.Inventors: Leanne Berry Ross, Gail Lewis Phillips, Mark X. Sliwkowski -
Patent number: 8728477Abstract: The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma.Type: GrantFiled: September 19, 2007Date of Patent: May 20, 2014Assignee: Immune Pharmaceuticals Ltd.Inventors: Jean Kadouche, Emmanuelle Sabbah-Petrover, Olivier Chose
-
Publication number: 20140134193Abstract: The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.Type: ApplicationFiled: October 31, 2013Publication date: May 15, 2014Applicant: PFIZER INC.Inventors: Chakrapani SUBRAMANYAM, Frank Erich KOEHN, Kenneth John DIRICO, Alessandra S. EUSTAQUIO, Michael Eric GREEN, Haiyin HE, Min HE, Christopher John O'DONNELL, Sujiet PUTHENVEETIL, Anokha RATNAYAKE, Jesse Alexander TESKE, Hui Yu YANG
-
Patent number: 8722047Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.Type: GrantFiled: April 5, 2010Date of Patent: May 13, 2014Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Publication number: 20140127240Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: May 8, 2014Applicants: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörißen, Sandra Brokowski
-
Publication number: 20140127197Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: ApplicationFiled: February 6, 2013Publication date: May 8, 2014Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Publication number: 20140127239Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.Type: ApplicationFiled: October 11, 2013Publication date: May 8, 2014Applicant: SPIROGEN SARLInventor: Philip Wilson HOWARD
-
Patent number: 8709432Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.Type: GrantFiled: March 30, 2012Date of Patent: April 29, 2014Assignee: ImmunoGen, Inc.Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
-
Patent number: 8703714Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.Type: GrantFiled: April 29, 2011Date of Patent: April 22, 2014Assignee: Seattle Genetics, Inc.Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Toni Beth Kline
-
Publication number: 20140105922Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: SEATTLE GENETICS, INC.Inventor: SEATTLE GENETICS, INC.
-
Publication number: 20140099258Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.Type: ApplicationFiled: November 13, 2013Publication date: April 10, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
-
Publication number: 20140093523Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicants: Immunogen, Inc., Janssen Biotech, Inc.Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
-
Publication number: 20140079721Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: August 9, 2013Publication date: March 20, 2014Applicant: Genentech, Inc.Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
-
Publication number: 20140079722Abstract: Antibodies targeting the dysadherin subunit of the human Na,K-ATPase signaling complex that are covalently linked via a stable linker to steroid drugs that bind the alpha subunit of that complex are useful in the treatment of cancer.Type: ApplicationFiled: March 9, 2012Publication date: March 20, 2014Applicant: CENTROSE, LLCInventor: James R. Prudent
-
Patent number: 8673303Abstract: The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.Type: GrantFiled: August 19, 2011Date of Patent: March 18, 2014Assignee: Biogen Idec MA Inc.Inventors: Michele Sanicola-Nadel, Kevin P. Williams, Susan Gail Schiffer, Paul Rayhorn
-
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
Patent number: 8663643Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: March 10, 2009Date of Patent: March 4, 2014Assignee: Genentech, Inc.Inventors: Leanne Berry, Gail Lewis Phillips, Mark X. Sliwkowski